The first comprehensive European advice on deep vein thrombosis was recently published in the European Heart Journal. The recommendations were produced by the European Society of Cardiology (ESC) Working Group on Aorta and Peripheral Vascular Diseases and Working Group on Pulmonary Circulation and Right Ventricular Function.
Inari Medical has announced that it has completed enrolment of its investigational device exemption (IDE) study. The FlowTriever Pulmonary Embolectomy Clinical Study (FLARE) study is designed to evaluate the safety and effectiveness of the FlowTriever Retrieval/Aspiration System for the treatment of pulmonary embolism.
Endovascular treatment of iliocaval and infrainguinal post-thrombotic venous obstruction results do not appear to be adversely affected by extension of the iliac vein stents into the femoral venous system, according to a US report in the Journal of Vascular Surgery: Venous and Lymphatic Diseases.
While comparative study data for venous stents are still lacking, results of a number of ongoing and planned venous stent trials will increase the options currently available to physicians and provide useful comparative data, explained Stephen Black (London, UK), giving a venous stent trial update at the 2017 THE VEINS at VIVA meeting (10–11 September, Las Vegas, USA).
Inferior vena cava (IVC) filters have been a highly controversial topic in the field of venous medicine due to the high rates of complications associated with their use, which eventually prompted a 2010 US Food and Drug Administration (FDA) advisory and declining use. This year, an article by the editor of JAMA Internal Medicine—Rita F Redberg (University of California, San Francisco, USA)—suggested, “There should be a moratorium on [IVC filter] use unless or until there are data showing efficacy greater than risk.” At the 2017 THE VEINS at VIVA meeting (10–11 September, Las Vegas, USA) Venous News spoke to John Kaufman (Dotter Interventional Institute, Portland, USA) to hear his opinion on the moratorium call, and how IVC filter use can be optimised for the safest and the best outcomes.
The US Centers for Medicare and Medicaid Services (CMS) has posted the 2018 Medicare Physician Fee Schedule (CMS-1678-F) and Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems (CMS-1678-FC). As part of the final rulings, healthcare providers will now be able to bill for VenaSeal utilising the new CPT codes 36482 and 36483. These new codes will take effect on 1 January, 2018.
Cardiff Metropolitan University has successfully secured funding to support an interdisciplinary collaboration arising from the Welsh Crucible programme that looks at the design and development of an innovative sterilising device for venous access ports (VAPs).
Cardiff Metropolitan University has announced it has secured a grant to “support an interdisciplinary collaboration of an innovative sterilising device for venous access ports (VAPs).”
At THE VEINS at VIVA meeting (10–11 September 2017, Las Vegas, USA), James Froehlich, University of Michigan, Ann Arbor, USA, reviewed guidelines on the management of superficial venous thrombosis (SVT) and emphasised the importance of performing duplex ultrasound in the examination, assessing clot location and extent, considering the risk factors for recurrence and development of deep vein thrombosis (DVT), and discussing with the patient their options on the use of anticoagulants.
At the THE VEINS at VIVA meeting (10–11 September, Las Vegas, USA), Esther Kim (Vanderbilt University Medical Center, Nashville, USA) gave a presentation on venous thrombosis in unusual locations, noting that such thromboses tend to occur in younger patients and those with malignancy, and that thrombophilia has a role in most cases and testing for it may be considered.
The first patient has been enrolled in Bolton Medical’s RelayPro US Food and Drug Administration (FDA) Phase II clinical trial.
Preliminary 30-day data from the PRELUDE trial investigating the use of the Serranator Alto percutaneous transluminal angioplasty (PTA) serration balloon catheter (Cagent Vascular) have shown 100% technical success and good effectiveness in moderate to severe calcification in the superficial femoral artery. The acute results show that the balloon can achieve low residual stenosis, and final six-month results are expected by the end of 2017.
New ACT 1 subgroup analysis demonstrates that in female patients the rate of ipsilateral stroke is lower with carotid artery stenting (CAS) compared with endarterectomy (CEA), while in highly atherosclerotic patients stenting seems to deliver better overall long-term results than endarterectomy.
Drug-eluting technologies, such as balloons coated with paclitaxel (DCB), are now the gold standard treatment for patients presenting with symptomatic peripheral artery disease (PAD) in the femoropopliteal region. DCBs have shown better clinical outcomes against uncoated balloons (PTA) for the treatment of femoropopliteal disease in large multicentre trials. After the introduction of the first DCB (Lutonix’s 0.035 over-the-wire DCB) there have been several entrants into the market. However, multiple clinical and pre-clinical studies have illustrated there are differences in performance and safety between the different products.
Over the past few years, we have seen an increased awareness of the role of mental health in several health outcomes, note Marlene Grenon and Greg J Zahner. One may wonder what is happening with our patients who suffer from vascular diseases; are they similarly affected by mental health diseases? While the rising toll of peripheral artery disease (PAD) on our world’s ageing population is no secret to the vascular surgeon, depression has quietly become the second leading cause of years lived with disability.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos